Hormone Receptor Expression Varies by Molecular Subtype, Age, and Sex in Pheochromocytoma and Paraganglioma: A Transcriptomic Analysis
Purpose The role of hormone receptor (HR) signaling in pheochromocytoma and paraganglioma (PCPG) is incompletely defined. We characterized HR expression across PCPG molecular subtypes and its clinicopathologic, transcriptional, and outcome associations. Methods RNA-sequencing data from 151 primary tumors (one per patient) in The Cancer Genome Atlas were analyzed for ESR1, ESR2, GPER1, PGR, AR, LHCGR, and the glucocorticoid receptor gene NR3C1. Expression was compared by molecular cluster (pseudohypoxia, kinase signaling, Wnt-altered), age, sex, and metastatic status using non-parametric tests. Event-free survival (EFS) was assessed with Cox models, and ESR1- and AR-associated programs with gene set enrichment analysis. Cluster patterns were tested in the independent E-MTAB-733 cohort. Results Pseudohypoxia tumors had higher ESR1 and PGR and lower LHCGR expression than other clusters (all p < 0.001), a pattern seen in both sexes. Kinase-signaling tumors had lower GPER1 and AR expression. NR3C1 did not differ by cluster. ESR1 and PGR decreased and LHCGR increased with age, predominantly in male patients. Lower LHCGR in pseudohypoxia tumors and lower AR in kinase-signaling tumors were associated with metastatic disease. No receptor was associated with EFS; overall survival could not be modeled (five deaths). In pseudohypoxia tumors, ESR1-high cases showed immune-enriched programs and AR-high cases developmental programs with oxidative phosphorylation depletion. Externally, cluster differences in PGR, LHCGR, AR, and GPER1, but not ESR1, were reproduced. Conclusion HR expression in PCPG varies by molecular subtype, age, and sex, and selected receptors track with metastatic behavior and distinct transcriptional programs. Protein-level validation and larger outcome-annotated cohorts are needed.
Authors
- Naris Nilubol (ORCID: https://orcid.org/0000-0002-7348-7804)
- Rachyl M. Shanker (ORCID: https://orcid.org/0000-0002-9920-1296)
- Lindsay F. Remer (ORCID: https://orcid.org/0000-0002-3405-2162)
- Genevieve F. Gilson
Institutions
- National Cancer Institute (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11393304/v1
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- preprint